Literature DB >> 22344869

Joint analysis of bivariate longitudinal ordinal outcomes and competing risks survival times with nonparametric distributions for random effects.

Ning Li1, Robert M Elashoff, Gang Li, Chi-Hong Tseng.   

Abstract

We propose a semiparametric joint model for bivariate longitudinal ordinal outcomes and competing risks failure time data. The association between the longitudinal and survival endpoints is captured by latent random effects. This approach generalizes previous joint analysis that considers only one response variable at the longitudinal endpoint. One unique feature of the proposed model is that we relax the commonly used normality assumption for random effects and leave the distribution completely unspecified. We use a modified version of the vertex exchange method in conjunction with an expectation-maximization algorithm to estimate the random effects distribution and model parameters. We show via simulations that robust parameter estimates are obtained from the proposed method under various scenarios. We illustrate the approach using cough severity and frequency data from a scleroderma lung study.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22344869     DOI: 10.1002/sim.4507

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

1.  Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II.

Authors:  Elizabeth R Volkmann; Donald P Tashkin; Myung Sim; Ning Li; Dinesh Khanna; Michael D Roth; Philip J Clements; Anna-Maria Hoffmann-Vold; Daniel E Furst; Grace Kim; Jonathan Goldin; Robert M Elashoff
Journal:  J Rheumatol       Date:  2019-02-15       Impact factor: 4.666

2.  Assessing Importance of Biomarkers: a Bayesian Joint Modeling Approach of Longitudinal and Survival Data with Semicompeting Risks.

Authors:  Fan Zhang; Ming-Hui Chen; Xiuyu Julie Cong; Qingxia Chen
Journal:  Stat Modelling       Date:  2020-07-27       Impact factor: 2.039

3.  Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.

Authors:  Elizabeth R Volkmann; Donald P Tashkin; Ning Li; Michael D Roth; Dinesh Khanna; Anna-Maria Hoffmann-Vold; Grace Kim; Jonathan Goldin; Philip J Clements; Daniel E Furst; Robert M Elashoff
Journal:  Arthritis Rheumatol       Date:  2017-05-23       Impact factor: 15.483

4.  Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II.

Authors:  Elizabeth R Volkmann; Donald P Tashkin; Holly LeClair; Michael D Roth; Grace Kim; Jonathan Goldin; Philip J Clements; Daniel E Furst; Dinesh Khanna
Journal:  ACR Open Rheumatol       Date:  2020-05-20

5.  The Effect of MSM and CD4+ Count on the Development of Cancer AIDS (AIDS-defining Cancer) and Non-cancer AIDS in the HAART Era.

Authors:  Prosanta Mondal; Hyun J Lim
Journal:  Curr HIV Res       Date:  2018       Impact factor: 1.581

6.  Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Authors:  Donald P Tashkin; Michael D Roth; Philip J Clements; Daniel E Furst; Dinesh Khanna; Eric C Kleerup; Jonathan Goldin; Edgar Arriola; Elizabeth R Volkmann; Suzanne Kafaja; Richard Silver; Virginia Steen; Charlie Strange; Robert Wise; Fredrick Wigley; Maureen Mayes; David J Riley; Sabiha Hussain; Shervin Assassi; Vivien M Hsu; Bela Patel; Kristine Phillips; Fernando Martinez; Jeffrey Golden; M Kari Connolly; John Varga; Jane Dematte; Monique E Hinchcliff; Aryeh Fischer; Jeffrey Swigris; Richard Meehan; Arthur Theodore; Robert Simms; Suncica Volkov; Dean E Schraufnagel; Mary Beth Scholand; Tracy Frech; Jerry A Molitor; Kristin Highland; Charles A Read; Marvin J Fritzler; Grace Hyun J Kim; Chi-Hong Tseng; Robert M Elashoff
Journal:  Lancet Respir Med       Date:  2016-07-25       Impact factor: 30.700

7.  Joint modelling of time-to-event and multivariate longitudinal outcomes: recent developments and issues.

Authors:  Graeme L Hickey; Pete Philipson; Andrea Jorgensen; Ruwanthi Kolamunnage-Dona
Journal:  BMC Med Res Methodol       Date:  2016-09-07       Impact factor: 4.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.